Shmuel Yitzhaki
Ness Ziona, M, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults.
Journal: Vaccine
Published: February 05, 2025
PEG-fibrinogen hydrogel microspheres as a scaffold for therapeutic delivery of immune cells.
Journal: Frontiers in bioengineering and biotechnology
Published: March 27, 2022
rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits.
Journal: Archives of toxicology
Published: March 16, 2022
Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs.
Journal: Archives of toxicology
Published: October 04, 2021
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies.
Journal: Antibodies (Basel, Switzerland)
Published: September 16, 2021
Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV-ΔG-Spike Vaccination Efficacy.
Journal: Frontiers in bioengineering and biotechnology
Published: July 07, 2021
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.
Journal: Nature communications
Published: October 18, 2020
Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Early Manifestations of COVID-19 in Israel.
Journal: Microbiology resource announcements
Published: July 11, 2020
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Journal: Nature communications
Published: June 18, 2020
Last Updated: 09/26/2026